Optimized immunohistochemistry in combination with image analysis: A reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer

Breast

Volumn 22, Issue 5, 2013, Pages 736-743

  Lang, D S ^a   Heilenkotter U ^b   Schumm, W ^c   Behrens, O ^b   Simon, R ^d   Vollmer, E ^a   Goldmann, T ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b Holsteinisches Breast Center   (Germany)

^c Department of Aquatic Toxicology Pathology Bavarian Environment Agency   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer; ELISA; HOPE fixation; Plasminogen activator inhibitor 1; Semiquantitative image analysis; Urokinase type plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FROZEN SECTION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATIENT CODING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RELIABILITY; RISK ASSESSMENT; RISK GROUP DISCRIMINATION; TISSUE FIXATION; TISSUE MICROARRAY;

BREAST CANCER; ELISA; HOPE FIXATION; PLASMINOGEN ACTIVATOR INHIBITOR-1; SEMIQUANTITATIVE IMAGE ANALYSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK ASSESSMENT; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84884157423     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.12.011     Document Type: Article

References (31)

1. Han B., Nakamura M., Mori I., Nakamura Y., Kakudo K. Urokinase-type plasminogen activator system and breast cancer (review). Oncol Rep 2005, 14:105-112.
2. Dublin E., Hanby A., Patel N.K., Liebman R., Barnes D. Immunohistochemical expression of UPA, uPAR, and PAI-1 in breast carcinoma. Am J Pathol 2000, 157:1219-1227.
3. Carriero M.V., Franco P., Del Vecchio S., Massa O., Botti G., D'Aiuto G., et al. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 1994, 54:5445-5454.
4. Dellas C., Loskutoff D.J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005, 93:631-640.
5. Kortlever R.M., Bernards R. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle 2006, 5:2697-2703.
6. Schmitt M., Harbeck N., Brünner N., Jänicke F., Meisner C., Mühlenweg B., et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011, 11(6):617-634.
7. Annecke K., Schmitt M., Euler U., Zerm M., Paepke D., Paepke S., et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008, 45:31-45.
8. Benraad Th.J., Geurts-Moespot J., Grondahl-Hansen J., Schmitt M., Heuvel J.J.T.M., deWitte J.H., et al. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer 1994, 32A(8):1371-1381.
9. Sweep C.G., Geurts-Moespot J., Grebenschikov N., de Witte J.H., Heuvel J.J., Schmitt M., et al. External quality assessment of trans-European multicenter antigen determination (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type1 inhibitor (PAI-1) in human breast cancer extracts. Br J Cancer 1998, 78:1434-1441.
10. Constantini V., Sidoni A., Deveglia R., Cazzato O.A., Bellezza G., Ferri I., et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 1996, 77:1079-1087.
11. Schneider J., Pollan M., Tejerina A., Sanchez J., Lucas A.R. Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br J Cancer 2003, 88:96-101.
12. Minisini A.M., Fabbro D., Di Loreto C., Pestrin M., Russo S., Cardellino G.G., et al. Markers of the uPA system and common prognostic factors in breast cancer. Am J Clin Pathol 2007, 128:1112-1117.
13. Jänicke F., Schmitt M., Hafter R., Hollrieder A., Babic R., Ulm K., et al. The urokinase-type plasminogen activator (uPA) is a potent predictor of early relapse in breast cancer. Fibrinolysis 1990, 4:69-78.
14. Reillly D., Christensen L., Duch M., Nolan N., Duffy M.J., Andreasen P.A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992, 50:208-214.
15. Ferrier C.M., de Witte H.H., Straatman H., van Tienoven D.H., van Geloof W.L., Rietveld F.J.R., et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer 1999, 79:1534-1541.
16. Olert J., Wiedorn K.H., Goldmann T., Kühl H., Mehraein Y., Scherthan F., et al. HOPE-fixation: a novel fixing method and paraffin-embedding technique for human soft tissues. Pathol Res Pract 2001, 197:823-826.
17. Goldmann T., Droemann D., Marzouki M., Schimmel U., Debel K., Branscheid D., et al. Tissue microarrays from HOPE-fixed specimens allow for enhanced high throughput molecular analyses in paraffin-embedded material. Pathol Res Pract 2005, 201:599-602.
18. Goldmann T., Vollmer E., Gerdes J. What's cooking? Detection of important biomarkers in HOPE-fixed paraffin embedded tissues eliminates the need for antigen retrieval. Am J Pathol 2003, 163:2638-2640.
19. Wilson E., Jacksons S., Cruwys S., Kerry P. An evaluation of the immunohistochemistry benefits of boric acid antigen retrieval on rat decalcified joint tissues. JImmunol Methods 2007, 322:137-142.
20. Schulz H., Kähler D., Branscheid D., Vollmer E., Zabel P., Goldmann T. TKTL1 is overexpressed in a large portion of non-small cell lung cancer specimens. Diagn Pathol 2008, 3-35.
21. Goldmann T., Suter l, Ribbert D., Otto F. The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predicts metastasis. Pathol Res Pract 1999, 195:171-175.
22. Harbeck N., Dettmar P., Thomsen C., Berger U., Ulm K., Kates R., et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 1999, 80:419-426.
23. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JClin Oncol 2007, 33:5287-5321.
24. Look M.P., van Putten W.L.J., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. JNatl Cancer Inst 2002, 94:116-128.
25. Vollmer E., Galle J., Lang D.S., Loeschke S., Schultz H., Goldmann T. The HOPE technique opens up a multitude of new possibilities in pathology. Rom J Morphol Embryol 2006, 47(1):15-19. [Review].
26. Goldmann T., Burgemeister R., Sauer U., Loeschke S., Lang D.S., Branscheid D., et al. Enhanced molecular analyses by combination of the HOPE-technique and laser microdissection. Diagn Pathol 2006, 1:2.
27. Ossowski L., Clunie G., Masucci M., Blasi F. Invivo paracrine interaction between urokinase and its receptor: effect on tumor invasion. JCell Biol 1991, 115:1107-1112.
28. Hildenbrandt R., Schaaf A. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 2009, 34:15-23.
29. Buo L., Meling G.I., Karlsrud T.S., Johansen H.A.T., Aasen A.O. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 1995, 26:1133-1138.
30. Haas S., Park T.-W., Hahne J.C., Fischer H.-P. Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue. Vir Arch 2008, 452:277-283.
31. Harbeck N., Kates R.E., Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. JClin Oncol 2002, 20:1000-1007.